Robeco Institutional Asset Management B.V. Raises Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Robeco Institutional Asset Management B.V. increased its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 1,293.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 380,960 shares of the biotechnology company's stock after purchasing an additional 353,624 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.24% of Ironwood Pharmaceuticals worth $1,570,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. CWM LLC increased its position in shares of Ironwood Pharmaceuticals by 55.1% during the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 2,345 shares during the last quarter. Diversified Trust Co purchased a new stake in Ironwood Pharmaceuticals in the 3rd quarter worth approximately $52,000. Legacy Capital Group California Inc. purchased a new stake in Ironwood Pharmaceuticals in the 3rd quarter worth approximately $59,000. GAMMA Investing LLC increased its holdings in Ironwood Pharmaceuticals by 344.1% in the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company's stock worth $69,000 after acquiring an additional 8,156 shares in the last quarter. Finally, First Dallas Securities Inc. purchased a new stake in Ironwood Pharmaceuticals in the 2nd quarter worth approximately $73,000.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on IRWD shares. Wells Fargo & Company reduced their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an "overweight" rating for the company in a report on Friday, August 9th. Leerink Partners began coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They set a "market perform" rating and a $5.00 price objective for the company. StockNews.com raised shares of Ironwood Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Monday, November 4th. Capital One Financial lowered shares of Ironwood Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $12.00 to $4.00 in a report on Thursday, August 8th. Finally, Craig Hallum cut their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a "buy" rating for the company in a report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $10.40.

Insiders Place Their Bets

In related news, insider Minardo John sold 9,910 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the sale, the insider now owns 284,661 shares of the company's stock, valued at $1,215,502.47. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 12.90% of the company's stock.

Ironwood Pharmaceuticals Stock Performance

IRWD traded up $0.30 on Friday, hitting $4.96. The company had a trading volume of 1,569,955 shares, compared to its average volume of 1,193,872. The stock has a fifty day moving average price of $4.32 and a 200-day moving average price of $5.59. Ironwood Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $15.70. The stock has a market capitalization of $792.31 million, a price-to-earnings ratio of -165.33 and a beta of 0.47.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.07). The business had revenue of $91.60 million during the quarter, compared to analyst estimates of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 6.37% and a net margin of 2.30%. Ironwood Pharmaceuticals's revenue was down 19.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.12 EPS. Analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.28 EPS for the current fiscal year.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.